Compare Consolidated Edison, Inc. (ED) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs GSK plc — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 2.3× Consolidated Edison, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and GSK plc for 93 Days on average.
| ED | GSK | |
|---|---|---|
Market Cap | $39.20B | $91.88B |
Volume | 2,142,900 | 7,730,529 |
Sector | Utilities | Health |
52-Week High | $115.46 | $61.18 |
52-Week Low | $95.37 | $43.24 |
Typical Hold Time | 75 Days | 93 Days |
Enterprise Value | $66.05B | $111.88B |
Dividend Yield | 3.31% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $105.94, up 1.23% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals reflect steady utility performance with 2025 revenue of $16.92B and net income of $2.02B. Recent news highlights its $24.8B economic impact in New York and upcoming investor webcast, reinforcing its stable dividend aristocrat status.
ED offers a defensive investment with a reliable dividend and moderate growth, but faces risks from high debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings, suggesting limited near-term upside despite solid cash flow generation. The stock's appeal lies in its income stability amid economic uncertainty, though execution on capital expenditures remains key to sustaining growth.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
